These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16861259)

  • 1. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer.
    Castronovo V; Waltregny D; Kischel P; Roesli C; Elia G; Rybak JN; Neri D
    Mol Cell Proteomics; 2006 Nov; 5(11):2083-91. PubMed ID: 16861259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis.
    Conrotto P; Roesli C; Rybak J; Kischel P; Waltregny D; Neri D; Castronovo V
    Int J Cancer; 2008 Dec; 123(12):2856-64. PubMed ID: 18798264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature.
    Roesli C; Neri D; Rybak JN
    Nat Protoc; 2006; 1(1):192-9. PubMed ID: 17406232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pivotal role of reactivity in the design of novel biotinylation reagents for the chemical-proteomics-based identification of vascular accessible biomarkers.
    Hanke SA; Kerner A; Nadler WM; Trumpp A; Zhang Y; Rösli CP
    J Proteomics; 2016 Jun; 141():57-66. PubMed ID: 27113135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel comprehensive approach for accessible biomarker identification and absolute quantification from precious human tissues.
    Turtoi A; Dumont B; Greffe Y; Blomme A; Mazzucchelli G; Delvenne P; Mutijima EN; Lifrange E; De Pauw E; Castronovo V
    J Proteome Res; 2011 Jul; 10(7):3160-82. PubMed ID: 21534635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical proteomic and bioinformatic strategies for the identification and quantification of vascular antigens in cancer.
    Strassberger V; Fugmann T; Neri D; Roesli C
    J Proteomics; 2010 Sep; 73(10):1954-73. PubMed ID: 20538087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature.
    Rybak JN; Ettorre A; Kaissling B; Giavazzi R; Neri D; Elia G
    Nat Methods; 2005 Apr; 2(4):291-8. PubMed ID: 15782212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of accessible human cancer biomarkers using ex vivo chemical proteomic strategies.
    Kischel P; Waltregny D; Castronovo V
    Expert Rev Proteomics; 2007 Dec; 4(6):727-39. PubMed ID: 18067412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies.
    Turtoi A; De Pauw E; Castronovo V
    Am J Pathol; 2011 Jan; 178(1):12-8. PubMed ID: 21224037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma.
    Turtoi A; Musmeci D; Wang Y; Dumont B; Somja J; Bevilacqua G; De Pauw E; Delvenne P; Castronovo V
    J Proteome Res; 2011 Sep; 10(9):4302-13. PubMed ID: 21755970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases.
    Rybak JN; Roesli C; Kaspar M; Villa A; Neri D
    Cancer Res; 2007 Nov; 67(22):10948-57. PubMed ID: 18006840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method.
    Castronovo V; Kischel P; Guillonneau F; de Leval L; Deféchereux T; De Pauw E; Neri D; Waltregny D
    Proteomics; 2007 Apr; 7(8):1188-96. PubMed ID: 17372937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved protein sequence coverage by on resin deglycosylation and cysteine modification for biomarker discovery.
    Kamada H; Fugmann T; Neri D; Roesli C
    Proteomics; 2009 Feb; 9(3):783-7. PubMed ID: 19137555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease-resistant streptavidin for interaction proteomics.
    Rafiee MR; Sigismondo G; Kalxdorf M; Förster L; Brügger B; Béthune J; Krijgsveld J
    Mol Syst Biol; 2020 May; 16(5):e9370. PubMed ID: 32400114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A highly sensitive detection method for immunohistochemistry using biotinylated tyramine.
    King G; Payne S; Walker F; Murray GI
    J Pathol; 1997 Oct; 183(2):237-41. PubMed ID: 9390040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass spectrometry based proteomics for absolute quantification of proteins from tumor cells.
    Wang H; Hanash S
    Methods; 2015 Jun; 81():34-40. PubMed ID: 25794949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Targeted therapy: toward a clean and effective war against cancer].
    Castronovo V; Waltregny D; Detry O; Coimbra Marques C; De Roover A; Honoré P; De Pauw E; Turtoi A
    Rev Med Liege; 2009; 64 Spec No():20-3. PubMed ID: 20085011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of a Drug Discovery Method Targeted to Stromal Tissue].
    Kamada H
    Yakugaku Zasshi; 2016; 136(3):435-41. PubMed ID: 26935083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel intravascular drug delivery method using endothelial biotinylation and avidin-biotin binding.
    Hoya K; Guterman LR; Miskolczi L; Hopkins LN
    Drug Deliv; 2001; 8(4):215-22. PubMed ID: 11757779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.